

CURRICULUM VITAE

Jian Ding

Principle investigator, Professor for Antitumor Pharmacology

Shanghai Institute of Materia Medica, Chinese Academy of Science

Member of Chinese Academy of Engineering

Member of The Academy of Sciences for the Developing World(TWAS)

555 Zu Chong Zhi Road

Zhangjiang Hi-Tech Park

Shanghai 201203

P.R.China

Phone: + 86-21-50806079

Fax: +86-21-50807088

Email: jding@simm.ac.cn

• **Education**

Ph.D. in Pathology, Kyushu University, Fukuoka, Japan 1991.

M.A. in Pathology, Medical University of China, Shengyang, China, 1983.

B.S. in Pathology, Jiangxi Medical University, Nanchang, China, 1978.

• **Positions and Employment**

2014--present Dean, School of Pharmacy, University of Chinese Academy of Sciences, China

2014--present Chairman, Scientific committee, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

2004--2014 Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

1997--2004 Deputy Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China.

1996--1996 Visiting scholar, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo

1994--present Chief, Professor, Department of Antitumor Pharmacology Division, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

1992--1994 Postdoctoral fellow, Division of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

1983--1986 Assistant professor, Department of Pathology, Jiangxi Medical University, China

1980--1983 Faculty of Medicine, Department of Pathology, Zhongguo Medical University, China

- Other experience and Professional Members

2012--present Member, Editorial Board, Molecular Pharmacology

2009--present, Member, Editorial Board, Journal of Biological Chemistry

2007--present, Member, Editorial Board, Journal of Ethnopharmacology

2007--present, Member, Editorial Board, Cancer Biology & Therapy

2006--present, Editor-in-chief, Acta Pharmacologica Sinica

2003--present, Member, Editorial Board, European Journal of Pharmacology

- Honors

2016 Tan Jiazhen Life Science Achievement Award

2016 Outstanding Achievement in Science and Technology Award of The Chinese Academy of Sciences

2013 Second degree of National Natural Science Award

2015 Advanced workers of The Chinese Academy of Sciences

2012 National Excellent Scientist

2010 First Degree of Shanghai Science & Technology Awards

2009 Second degree of National Natural Science Award

2008 Prizer of Scietific and Technological Progress of Ho Leung Ho Lee Foundation

2007 First Degree of Shanghai Science & Technology Awards

2006 Wu Jieping Medical - Paul Janssen Pharmaceutical Research Award

2005 One of ten excellent Scientists of Shanghai

2004 Second Degree of National Science & Technology Awards

2002 First Degree of Shanghai Science & Technology Awards

2001 The Fourth International Debio-CCRF Award

1998 Third Degree of National Science & Technology Awards

- Major research interests

Dr. Ding's laboratory is mainly focused on:(1) discovery and development of molecularly targeted anticancer drugs targeting tyrosine kinases,PI3K/mTOR pathway, epigenetic modulators and tumor angiogenesis regulators; (2) exploring molecular mechanisms of anticancer drugs, particularly signaling transduction and molecular basis of drug resistance; (3) characterizing genomics-based new targets for the proof of concept of novel cancer therapies; (4) discovery of biomarkers for molecularly targeted therapies.

- Representative publications

1. Zeng H, Qu J, Jin N, Xu J, Lin C, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M, **Ding J***, Geng M. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylases inhibitors in breast cancer. *Cancer Cell*, 2016.
 2. Ai J, Tang Q, Wu Y, Xu Y, Teng F, Zhou R, Gao X, Zhu Q, Yue X, Pan Q, Xu S, Li J, Huang M, Daugherty-Holtrop J, He Y, Xu H, Fan J, **Ding J***, Geng M. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. *J Natl Cancer Inst*, 2011.
 3. Huang M, Shen A, **Ding J***, Geng M, Molecularly targeted cancer therapy: some lessons from the past decade. *Trends Pharmacol Sci.*, 2014.
 4. Shen A, Wang L, Huang M, Sun J, Chen Y, Shen Y, Yang X, Wang X, **Ding J***, Geng M. c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. *Cancer Res*, 2015.
 5. Liu H, Ai J, Shen A, Chen Y, Wang X, Peng X, Chen H, Shen Y, Huang M, **Ding J***, Geng M. c-Myc alteration determines the therapeutic response to FGFR inhibitors. *Clin Cancer Res*. 2016 .
 6. Sun W, Xie Z, Liu Y, Zhao D, Wu Z, Zhang D, Lv H, Tang S, Jin N, Jiang H, Tan M, **Ding J**, Luo C, Li J, Huang M, Geng M. JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. *Cancer Res*. 2015.
 7. Li X, Tong L, **Ding J***, Meng L. Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer. *Cancer Lett*. 2014.
 8. Chen S, Guo C, Shi J, Xu Y, Chen Y, Shen Y, Su Y, **Ding J***, Meng L. HSP90 inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer. *Int J Cancer*. 2014
 9. Yu B, Miao Z, Jiang Y, Li M, Yang N, Li T, **Ding J***. c-Jun Protects Hypoxia-Inducible Factor-1{alpha} from Degradation via Its Oxygen-Dependent Degradation Domain in a Nontranscriptional Manner. *Cancer Res*. 2009.
 10. **Ding J***, Miao Z, Meng L. Emerging cancer therapeutic opportunities target DNA repair systems. *Trends in Pharmacol Sci*. 2006.
 11. Wang J, Ou Z, Hou Y, Luo J, Shen Z, **Ding J***, Shao Z. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. *Oncogene*. 2006.
 12. Huang M, Gao H, Chen Y, Zhu H, Cai Y, Zhang X, Miao Z, Jiang H, Shen H, Lin L, Lu W, **Ding J***. Chimmitecan, a Novel 9-Substituted Camptothecin, with Excellent Improvement in Anti-cancer Pharmacological Profiles both In Vitro and In Vivo. *Clin Cancer Res* 2007.
-